Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Bahadir Koylu"'
Autor:
Bahadir, Koylu, Busra, Firlatan, Suleyman Nahit, Sendur, Seda Hanife, Oguz, Selcuk, Dagdelen, Tomris, Erbas
Publikováno v:
Endocrine.
Since giant (≥40 mm) GH-secreting pituitary adenomas are rarely encountered, data on their characteristics and treatment outcomes are limited. We aimed to investigate the characteristics of giant GH-secreting pituitary adenomas and to compare their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4b8d0e9911564469232dac9d23669b74
https://pubmed.ncbi.nlm.nih.gov/36318446
https://pubmed.ncbi.nlm.nih.gov/36318446
Autor:
Omer Diker, Recep Ak, Berna Oksuzoglu, Deniz Can Guven, Neyran Kertmen, Polat Olgun, Hakan Taban, Onur Bas, Bahadir Koylu, Burak Yasin Aktas, Sercan Aksoy
Publikováno v:
Cancer Research. 81:PS10-52
BackgroundInvasive breast cancers are characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) approximately 15 to 25%. Survival outcomes was improved after introduction of Trastuzumab treatment. Trastuz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5d173d14311af24f7926ba278f2ed84
https://doi.org/10.1158/1538-7445.sabcs20-ps10-52
https://doi.org/10.1158/1538-7445.sabcs20-ps10-52
Autor:
Burak Yasin Aktas, Polat Olgun, Berna Oksuzoglu, Bahadir Koylu, Deniz Can Guven, Recep Ak, Sercan Aksoy, Hakan Taban, Omer Diker, Neyran Kertmen, Omer Dizdar, Onur Bas
Publikováno v:
Future oncology (London, England). 18(3)
Background: In node-negative HER2-overexpressed breast cancers, adjuvant paclitaxel plus trastuzumab treatment is a successful de-escalation approach with excellent survival outcomes. Methods: All patients with HER2+ breast cancer treated in our cent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03abbe92e265634e865e7b417cb0763a
https://pubmed.ncbi.nlm.nih.gov/34758639
https://pubmed.ncbi.nlm.nih.gov/34758639
Autor:
Suleyman Nahit Sendur, Bahadir Koylu, Busra Firlatan, Hanife Seda Oguz, Selcuk Dagdelen, Tomris Erbas
Publikováno v:
Journal of the Endocrine Society. 6:A491-A491
Objectives Since the literature about giant (≥40 mm)pituitary somatotroph adenomas is limited to case reports, we aimed to summarize the characteristics of our giant somatotroph pituitary adenoma cohort and compare their clinical features and treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e892b302922735ca38aa58fbc5f467
https://doi.org/10.1210/jendso/bvac150.1020
https://doi.org/10.1210/jendso/bvac150.1020
Pazopanib is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC). It is an anti-angiogenic agent, which blocks the activation signaling pathways of tyrosine kinases and prevents the activities of primarily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaab60d6f2dfce1da189351dc6edf190
https://hdl.handle.net/20.500.12713/2005
https://hdl.handle.net/20.500.12713/2005
Publikováno v:
Journal of the Endocrine Society
The prevalence of growth hormone (GH)-secreting pituitary adenoma is around 11-13% of all pituitary adenomas. Giant GH-secreting pituitary adenomas (≥ 4 cm) are rare tumors, and its prevalence of among acromegalic patients is This is a retrospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68fabee879977fe59288ac1cec4cda3e
https://doi.org/10.1210/jendso/bvaa046.1110
https://doi.org/10.1210/jendso/bvaa046.1110